Meditor Group Ltd → EXELIXIS, INC. EXEL

Stake: — Shares: —

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

1 transaction

0 buys · 1 sales · 0 awards/exercises

Issuer Cluster

6 13D/G filings on this issuer

5 other filings besides this one

Filer Track Record

3 filings by this filer

2 other filings in the data moat

Short Interest · settle 2026-08-31

DTC 14.88

28,656,285 shares short · +2.2% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $37.52M

Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-08-10	Beckerle Mary C	director	Sale	9,812	$53.66	$527K

Other 13D/G Filings on EXELIXIS, INC.

Filed	Form	Filer	Stake	Shares
2026-08-14	SCHEDULE 13D/A	FARALLON CAPITAL MANAGEMENT, L.L.C.	5.60%	13,989,010	view →
2026-01-05	SCHEDULE	Farallon Capital Partners, L.P.	5.90%	15,709,500	view →
2025-05-20	SCHEDULE	Farallon Capital Partners, L.P.	6.80%	18,635,500	view →
2025-03-05	SCHEDULE	Farallon Capital Partners, L.P.	8.40%	23,439,500	view →
2023-06-02	SC	Caligan Partners LP	—	—	view →

Other Filings by Meditor Group Ltd

Filed	Form	Issuer	Stake	Shares
2024-01-03	SC	Esperion Therapeutics, Inc. ESPR	—	—	view →
2018-01-03	SC	Esperion Therapeutics, Inc. ESPR	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →